1. Home
  2. ICUCW vs EICC Comparison

ICUCW vs EICC Comparison

Compare ICUCW & EICC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ICUCW
  • EICC
  • Stock Information
  • Founded
  • ICUCW N/A
  • EICC N/A
  • Country
  • ICUCW United States
  • EICC United States
  • Employees
  • ICUCW 19
  • EICC N/A
  • Industry
  • ICUCW Biotechnology: Pharmaceutical Preparations
  • EICC
  • Sector
  • ICUCW Health Care
  • EICC
  • Exchange
  • ICUCW Nasdaq
  • EICC Nasdaq
  • Market Cap
  • ICUCW N/A
  • EICC N/A
  • IPO Year
  • ICUCW 2021
  • EICC N/A
  • Fundamental
  • Price
  • ICUCW N/A
  • EICC $25.18
  • Analyst Decision
  • ICUCW
  • EICC
  • Analyst Count
  • ICUCW 0
  • EICC 0
  • Target Price
  • ICUCW N/A
  • EICC N/A
  • AVG Volume (30 Days)
  • ICUCW N/A
  • EICC 18.7K
  • Earning Date
  • ICUCW N/A
  • EICC 01-01-0001
  • Dividend Yield
  • ICUCW N/A
  • EICC 7.96%
  • EPS Growth
  • ICUCW N/A
  • EICC N/A
  • EPS
  • ICUCW N/A
  • EICC 0.55
  • Revenue
  • ICUCW N/A
  • EICC $51,224,692.00
  • Revenue This Year
  • ICUCW N/A
  • EICC $39.61
  • Revenue Next Year
  • ICUCW N/A
  • EICC $27.28
  • P/E Ratio
  • ICUCW N/A
  • EICC $23.44
  • Revenue Growth
  • ICUCW N/A
  • EICC 68.61
  • 52 Week Low
  • ICUCW N/A
  • EICC $23.75
  • 52 Week High
  • ICUCW N/A
  • EICC $25.25
  • Technical
  • Relative Strength Index (RSI)
  • ICUCW N/A
  • EICC N/A
  • Support Level
  • ICUCW N/A
  • EICC N/A
  • Resistance Level
  • ICUCW N/A
  • EICC N/A
  • Average True Range (ATR)
  • ICUCW 0.00
  • EICC 0.00
  • MACD
  • ICUCW 0.00
  • EICC 0.00
  • Stochastic Oscillator
  • ICUCW 0.00
  • EICC 0.00

About ICUCW SeaStar Medical Holding Corporation Warrant

SeaStar Medical Holding Corp is a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs. It is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. The Company is comprised of a single reportable segment, which is its Device Segment.

About EICC Eagle Point Income Company Inc. 8.00% Series C Term Preferred Stock due 2029

Eagle Point Income Co Inc is a closed-end management investment company. Its primary investment objective is to generate high current income, with a secondary objective to generate capital appreciation. The Company seeks to achieve its investment objectives by investing in junior debt tranches of collateralized loan obligations, or "CLOs," that are collateralized by a portfolio consisting of below-investment grade U.S. senior secured loans with a large number of distinct underlying borrowers across various industry sectors.

Share on Social Networks: